Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Deloitte
McKesson
Mallinckrodt
Cerilliant
Chinese Patent Office
AstraZeneca
US Department of Justice
Accenture

Generated: April 25, 2018

DrugPatentWatch Database Preview

Claims for Patent: 3,624,205

« Back to Dashboard

Summary for Patent: 3,624,205
Title: TREATMENT OF HYPERURICEMIA IN HUMANS
Abstract:The method of treatment and prophylaxis for hyperuricemia, which comprises administering to a human patient a therapeutically effective amount of a compound selected from the class consisting of 4-hydroxy-1-H-pyrazolo(3,4-d)pyrimidine and 4,6-dihydroxy-1-H-pyrazolo(3,4-d)pyrimidine.
Inventor(s): Hitchings; George H. (Yonkers, NY), Falco; Elvira A. (New Rochelle, NY)
Assignee: Burroughs Wellcome & Co. (U.S.A.) Inc. (Tuckahoe, NY)
Application Number:04/633,364
Patent Claims: 1. The method of treatment and prophylaxis for hyperuricemia, which comprises administering to a human patient a therapeutically effective amount of a compound 4-hydroxy-1-H-pyrazolo(3,4-d)pyrimidine.

2. The method of claim 1, wherein the compound 4-hydroxy-1-H-pyrazolo(3,4-d)pyrimidine is administered at a dosage of 2 to 30 mg./kg. of the body weight of the human patient treated.

3. The method of treatment and prophylaxis for hyperuricemia, which comprises administering to a human patient a therapeutically effective amount of a compound 4,6-dihydroxy-1-H-pyrazolo(3,4-d)pyrimidine.

4. The method claim 3, wherein the compound 4,6-dihydroxy-1-H-pyrazolo(3,4-d)pyrimidine is administered at a dosage of 2 to 30 mg./kg. of the body weight of the human patient treated.

5. The method of treatment and prophylaxis for hyperuricemia, which comprises administering to a human patient a therapeutically effective amount of a compound selected from the class consisting of 4-hydroxy-1-H-pyrazolo(3,4-d)pyrimidine and 4,6-dihydroxy-1-H-pyrazolo-(3,4-d)pyrimidine.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
McKinsey
Federal Trade Commission
Healthtrust
Daiichi Sankyo
Citi
Argus Health
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.